Studies reveal that 9.5% of the global population is affected by liver fibrosis, with males having a higher prevalence of getting affected than females. The prevalence in males is around 10.6% while 5.4% of females may get develop the condition once in a lifetime. Moreover, the prevalence increases with age. Therefore, there is a significant emphasis on developing quality medications that help in disease management effectively.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing liver fibrosis pipeline development activities. Moreover, liver fibrosis collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Nonalcoholic fatty liver disease (NAFLD) is the most common category of liver fibrosis, followed by alcoholic liver disease, which is due to long-term excesses of drinking alcohol. The liver fibrosis treatment varies based on the cause of illness and the symptoms of the patient. Some of the specific treatment alternatives include ACE inhibitors, direct-action antivirals, PPAR-alpha agonists and antifibrotics. Several universities and pharmaceutical companies are collaborating to develop high-efficacy drugs that manage the condition effectively. In March 2024, the United States FDA granted approval to Rezdiffra (resmetirom) for treating adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis). Such approvals indicate a promising landscape for the drugs in the disease pipeline.
ALG-055009
Aligos Therapeutics is conducting a Phase 2a study to investigate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of liver fibrosis drug candidate ALG-055009 (soft gelatin capsule) for 12 weeks. The study enrols 100 patients and is expected to be completed by December 2024.
This product will be delivered within 3-5 business days.
Report Coverage
The Liver Fibrosis Drug Pipeline Report by the publisher gives comprehensive insights into liver fibrosis drugs currently undergoing liver fibrosis clinical trials. It covers various aspects related to the details of each of these liver fibrosis drugs under development for Liver fibrosis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The liver fibrosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from liver fibrosis.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing liver fibrosis pipeline development activities. Moreover, liver fibrosis collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Liver Fibrosis Drug Pipeline Outlook
Liver fibrosis involves the formation of scar tissues in large amounts, formed as a response to repairing and replacing damaged liver cells. There are different levels of liver fibrosis which are primarily based on the degree of liver damage. The condition does not have many symptoms in the mild to moderate stages. As the patient progresses, they may encounter symptoms like appetite loss, difficulty thinking clearly, fluid buildup in the legs or stomach, jaundice (where the skin and eyes appear yellow nausea, unexplained weight loss or weakness.Nonalcoholic fatty liver disease (NAFLD) is the most common category of liver fibrosis, followed by alcoholic liver disease, which is due to long-term excesses of drinking alcohol. The liver fibrosis treatment varies based on the cause of illness and the symptoms of the patient. Some of the specific treatment alternatives include ACE inhibitors, direct-action antivirals, PPAR-alpha agonists and antifibrotics. Several universities and pharmaceutical companies are collaborating to develop high-efficacy drugs that manage the condition effectively. In March 2024, the United States FDA granted approval to Rezdiffra (resmetirom) for treating adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis). Such approvals indicate a promising landscape for the drugs in the disease pipeline.
Liver Fibrosis - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of liver fibrosis drug candidates based on several segmentations including:By Phase
The pipeline assessment report covers 50+ drug analyses based on phase.- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The liver fibrosis therapeutic assessment report covers 50+ drug analyses based on drug classes:
- Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonists
- ACE Inhibitors
- Hepatotropic Drugs
- Others
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Liver Fibrosis - Pipeline Assessment Segmentation, By Phases
The liver fibrosis report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for liver fibrosis. There are around 334 drugs in phase II of liver fibrosis drugs.Liver Fibrosis - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under liver fibrosis pipeline analysis include peroxisome proliferator-activated receptors (PPAR)-alpha agonists, ACE inhibitors, hepatotropic drugs and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for liver fibrosis.Liver Fibrosis Clinical Trials Therapeutic Assessment - Competitive Dynamics
The liver fibrosis drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Liver fibrosis clinical trials:- Eli Lilly and Company
- Gilead Sciences
- Intercept Pharmaceuticals
- Galectin Therapeutics
- Genfit
- Madrigal Pharmaceuticals
- Bristol-Myers Squibb (BMS)
- Novo Nordisk
Liver Fibrosis - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for liver fibrosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of liver fibrosis drug candidates.Tirzepatide
Previously approved for treating type 2 diabetes, Eli Lilly's metabolic disorder medication tirzepatide, currently under phase 2 clinical trial of a 52-week study demonstrated high efficacy against nonalcoholic steatohepatitis (NASH) with no worsening of the liver fibrosis.ALG-055009
Aligos Therapeutics is conducting a Phase 2a study to investigate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of liver fibrosis drug candidate ALG-055009 (soft gelatin capsule) for 12 weeks. The study enrols 100 patients and is expected to be completed by December 2024.
Reasons To Buy This Report
The Liver Fibrosis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for liver fibrosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into liver fibrosis collaborations, regulatory environments, and potential growth opportunities within liver fibrosis pipeline insights.Key Questions Answered in the Liver Fibrosis - Pipeline Insight Report
- Which companies/institutions are leading the liver fibrosis drug development?
- What is the efficacy and safety profile of liver fibrosis pipeline drugs?
- Which company is leading the liver fibrosis pipeline development activities?
- What is the current liver fibrosis commercial assessment?
- What are the opportunities and challenges present in the liver fibrosis drug pipeline landscape?
- What is the efficacy and safety profile of liver fibrosis pipeline drugs?
- Which company is conducting major trials for liver fibrosis drugs?
- Which companies/institutions are involved in liver fibrosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in liver fibrosis?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Liver Fibrosis
4 Patient Profile: Liver Fibrosis
5 Liver Fibrosis: Epidemiology Snapshot
6 Liver Fibrosis: Market Dynamics
7 Liver Fibrosis: Key Facts Covered
8 Liver Fibrosis, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Liver Fibrosis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Liver Fibrosis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Liver Fibrosis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Liver Fibrosis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Liver Fibrosis, Key Drug Pipeline Companies
